Edition:
United States

Immuron Ltd (IMC.AX)

IMC.AX on Australia Stock Exchange

0.46AUD
26 May 2017
Change (% chg)

$-0.09 (-16.36%)
Prev Close
$0.55
Open
$0.54
Day's High
$0.54
Day's Low
$0.46
Volume
154,901
Avg. Vol
107,741
52-wk High
$0.70
52-wk Low
$0.22

IMC.AX

Chart for IMC.AX

About

Immuron Limited is a biopharmaceutical company. The Company focuses on the research and development of bovine-colostrum enriched with antibodies of choice for the treatment and prevention of a range of infections and immune modulated diseases. The Company has three segments: Research and Development (R&D), HyperImmune Products... (more)
No analyst recommendations are available for IMC.AX.

Overall

Beta: -0.95
Market Cap(Mil.): $48.60
Shares Outstanding(Mil.): 105.64
Dividend: --
Yield (%): --

Financials

  IMC.AX Industry Sector
P/E (TTM): -- 14.27 17.41
EPS (TTM): -0.06 -- --
ROI: -198.19 -7.17 -5.42
ROE: -198.19 -6.63 -4.68

BRIEF-Immuron Ltd sees U.S. IPO priced at $10-$12.50 per ADS

* Immuron Ltd sees U.S. IPO priced between $10.00 and $12.50 per ads and $0.01 per warrant - sec filing

May 24 2017

BRIEF-Immuron expands agreement with U.S. army

* immuron expands agreement with us army to include 3 shigella therapeutics

May 16 2017

BRIEF-Immuron offering 416,667 ads and warrants to purchase 208,334 ads

* Says offering 416,667 ads and warrants to purchase 208,334 ads

May 08 2017

BRIEF-Immuron ltd announces positive results of IMM-124E in Acute Colitis research studies

* Immuron Ltd - announces positive results of imm-124e in acute colitis research studies

Apr 18 2017

BRIEF-Immuron receives $1.6m research and development tax concession refund

* Immuron receives $1.6m research and development tax concession refund Source text for Eikon: Further company coverage:

Nov 28 2016

More From Around the Web

Earnings vs. Estimates